Itovebi is part of a push by Roche to make new inroads in breast cancer. Elsewhere, Turnstone is trimming preclinical research and Gritstone bio is working on a bankruptcy deal.

In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

Pfizer Inc. faced a challenging day on the New York Stock Exchange, with its stock price dropping 2.1% to $29.57. Despite this setback, the pharmaceutical behemoth received positive news from a Phase ...

Pfizer's drug combination improves survival in prostate cancer patients. Starboard Value pressures Pfizer over board conduct.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...

On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...

Pfizer Inc.’s stock dipped 2.5% Thursday after two of its former executives said they would not support an effort by activist ...

Company also reports positive data from trial of combination treatment for a form of prostate cancer Pfizer Inc.'s stock dipped 2.5% Thursday after two of its former executives said they would not ...

Pfizer’s Talzenna-Xtandi combination has marked a major step forward in treating advanced prostate cancer, improving patient ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...